Jan 23, 2023 8:30am EST QSAM Biosciences to Present at the Emerging Growth Conference on Wednesday, January 25, 2023
Nov 15, 2022 8:00am EST QSAM Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Oct 26, 2022 8:00am EDT QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer
Aug 16, 2022 8:00am EDT QSAM Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Jul 13, 2022 1:32pm EDT QSAM Biosciences Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam®
May 17, 2022 8:00am EDT QSAM Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
Apr 28, 2022 7:00am EDT QSAM Biosciences Doses First Patient in its Clinical Trial for Cyclosam®, Radiopharmaceutical Drug Candidate for the Treatment of Bone Cancer
Apr 12, 2022 8:00am EDT QSAM Biosciences Receives Japanese Patent for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
